Posted by Michael Wonder on 25 Jun 2024
Oncoinvent receives FDA fast track designation for Radspherin as treatment for peritoneal carcinomatosis from ovarian cancer
24 June 2024 - Phase 2b trial of Radspherin to treat ovarian cancer patients expected to initiate imminently.
Oncoinvent today announced that the US FDA has granted fast track designation to Radspherin for the treatment of patients with peritoneal metastases from ovarian cancer.
